SG10201500274TA - Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists - Google Patents
Stable anti-tnfr1 polypeptides, antibody variable domains & antagonistsInfo
- Publication number
- SG10201500274TA SG10201500274TA SG10201500274TA SG10201500274TA SG10201500274TA SG 10201500274T A SG10201500274T A SG 10201500274TA SG 10201500274T A SG10201500274T A SG 10201500274TA SG 10201500274T A SG10201500274T A SG 10201500274TA SG 10201500274T A SG10201500274T A SG 10201500274TA
- Authority
- SG
- Singapore
- Prior art keywords
- antagonists
- variable domains
- antibody variable
- stable anti
- tnfr1 polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25523509P | 2009-10-27 | 2009-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201500274TA true SG10201500274TA (en) | 2015-03-30 |
Family
ID=43382391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201500274TA SG10201500274TA (en) | 2009-10-27 | 2010-10-25 | Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20150210767A1 (en) |
| EP (1) | EP2493504B1 (en) |
| JP (1) | JP2013507978A (en) |
| KR (1) | KR20120101417A (en) |
| CN (1) | CN102686239B (en) |
| AR (1) | AR078763A1 (en) |
| AU (1) | AU2010311640B2 (en) |
| BR (1) | BR112012010114A2 (en) |
| CA (1) | CA2777312A1 (en) |
| CL (1) | CL2012001055A1 (en) |
| CO (1) | CO6612254A2 (en) |
| CR (1) | CR20120197A (en) |
| DO (1) | DOP2012000113A (en) |
| EA (1) | EA022898B1 (en) |
| ES (1) | ES2552177T3 (en) |
| IL (1) | IL218860A0 (en) |
| MA (1) | MA33758B1 (en) |
| MX (1) | MX2012005024A (en) |
| NZ (1) | NZ599114A (en) |
| PE (1) | PE20121564A1 (en) |
| SG (1) | SG10201500274TA (en) |
| TW (1) | TW201125877A (en) |
| UA (1) | UA107200C2 (en) |
| UY (1) | UY32969A (en) |
| WO (1) | WO2011051217A1 (en) |
| ZA (1) | ZA201203052B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2398827A2 (en) * | 2009-02-19 | 2011-12-28 | Glaxo Group Limited | Improved anti-tnfr1 polypeptides, antibody variable domains&antagonists |
| US20140112929A1 (en) * | 2011-06-17 | 2014-04-24 | Glaxo Group Limited | Tumour necrosis factor receptor 1 antagonists |
| CN104936973A (en) * | 2013-01-31 | 2015-09-23 | 葛兰素集团有限公司 | Method of producing a protein |
| WO2015104322A1 (en) | 2014-01-09 | 2015-07-16 | Glaxosmithkline Intellectual Property Development Limited | Treatment of inflammatory diseases with non-competitive tnfr1 antagonists |
| AU2017245612B2 (en) * | 2016-04-05 | 2020-08-27 | Baliopharm Ag | Monovalent inhibitor of huTNFR1 interaction |
| IL300930A (en) | 2020-08-27 | 2023-04-01 | Enosi Therapeutics Corp | Methods and compositions to treat autoimmune diseases and cancer |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| CN114699533B (en) * | 2022-05-06 | 2023-05-09 | 郑州大学 | Preparation method and application of nucleic acid aptamer and polypeptide crosslinked double-target composite nucleic acid nano-drug |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (en) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | CHANGED ANTIBODIES. |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| JP3095168B2 (en) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | Antibodies with domain-denaturing constants |
| EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| ATE92107T1 (en) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN-CONTAINING FUSION PROTEINS. |
| US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| EP2258846A3 (en) | 1997-07-07 | 2012-03-21 | Medical Research Council | A method for increasing the concentration of a nucleic acid molecule |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US7148061B2 (en) | 2000-02-11 | 2006-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| JP4303105B2 (en) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | Dual specific ligands and their use |
| WO2004058821A2 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| US20060002935A1 (en) * | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| ATE328906T1 (en) | 2002-06-28 | 2006-06-15 | Domantis Ltd | DUAL-SPECIFIC LIGANDS WITH INCREASED HALF-LIFE |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| JP2006520584A (en) | 2002-11-08 | 2006-09-14 | アブリンクス エン．ヴェー． | Stabilized single domain antibody |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| EP1627062A1 (en) | 2003-05-14 | 2006-02-22 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| AU2004220325B2 (en) | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
| HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| CN101084014A (en) * | 2004-10-08 | 2007-12-05 | 杜门蒂斯有限公司 | Single domain antibodies against tnfr1 and methods of use therefor |
| GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| KR20100018040A (en) | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | Methods for selecting protease resistant polypeptides |
| EP2398827A2 (en) * | 2009-02-19 | 2011-12-28 | Glaxo Group Limited | Improved anti-tnfr1 polypeptides, antibody variable domains&antagonists |
| CA2767752C (en) * | 2009-02-19 | 2020-07-07 | Elena De Angelis | Improved anti-serum albumin binding variants |
-
2010
- 2010-10-25 AU AU2010311640A patent/AU2010311640B2/en not_active Ceased
- 2010-10-25 EA EA201290172A patent/EA022898B1/en not_active IP Right Cessation
- 2010-10-25 CA CA2777312A patent/CA2777312A1/en not_active Abandoned
- 2010-10-25 EP EP10774177.9A patent/EP2493504B1/en active Active
- 2010-10-25 UA UAA201204796A patent/UA107200C2/en unknown
- 2010-10-25 PE PE2012000560A patent/PE20121564A1/en not_active Application Discontinuation
- 2010-10-25 KR KR1020127013723A patent/KR20120101417A/en not_active Application Discontinuation
- 2010-10-25 TW TW099136369A patent/TW201125877A/en unknown
- 2010-10-25 AR ARP100103911A patent/AR078763A1/en unknown
- 2010-10-25 JP JP2012535767A patent/JP2013507978A/en active Pending
- 2010-10-25 CN CN201080059618.5A patent/CN102686239B/en not_active Expired - Fee Related
- 2010-10-25 BR BR112012010114A patent/BR112012010114A2/en not_active IP Right Cessation
- 2010-10-25 UY UY0001032969A patent/UY32969A/en not_active Application Discontinuation
- 2010-10-25 ES ES10774177.9T patent/ES2552177T3/en active Active
- 2010-10-25 WO PCT/EP2010/066046 patent/WO2011051217A1/en active Application Filing
- 2010-10-25 MX MX2012005024A patent/MX2012005024A/en not_active Application Discontinuation
- 2010-10-25 NZ NZ599114A patent/NZ599114A/en not_active IP Right Cessation
- 2010-10-25 SG SG10201500274TA patent/SG10201500274TA/en unknown
-
2012
- 2012-03-27 IL IL218860A patent/IL218860A0/en unknown
- 2012-03-29 CO CO12053463A patent/CO6612254A2/en unknown
- 2012-04-18 DO DO2012000113A patent/DOP2012000113A/en unknown
- 2012-04-23 CR CR20120197A patent/CR20120197A/en unknown
- 2012-04-25 ZA ZA2012/03052A patent/ZA201203052B/en unknown
- 2012-04-25 CL CL2012001055A patent/CL2012001055A1/en unknown
- 2012-05-18 MA MA34878A patent/MA33758B1/en unknown
-
2015
- 2015-04-09 US US14/682,176 patent/US20150210767A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012005024A (en) | 2012-09-07 |
| MA33758B1 (en) | 2012-11-01 |
| EA022898B1 (en) | 2016-03-31 |
| CO6612254A2 (en) | 2013-02-01 |
| KR20120101417A (en) | 2012-09-13 |
| TW201125877A (en) | 2011-08-01 |
| CR20120197A (en) | 2012-06-22 |
| PE20121564A1 (en) | 2012-11-29 |
| UA107200C2 (en) | 2014-12-10 |
| IL218860A0 (en) | 2012-06-28 |
| AU2010311640A1 (en) | 2012-05-10 |
| EP2493504A1 (en) | 2012-09-05 |
| US20150210767A1 (en) | 2015-07-30 |
| CL2012001055A1 (en) | 2012-10-05 |
| EP2493504B1 (en) | 2015-10-07 |
| ZA201203052B (en) | 2013-09-25 |
| ES2552177T3 (en) | 2015-11-26 |
| CN102686239B (en) | 2016-02-03 |
| WO2011051217A1 (en) | 2011-05-05 |
| CN102686239A (en) | 2012-09-19 |
| DOP2012000113A (en) | 2012-08-15 |
| EA201290172A1 (en) | 2013-04-30 |
| AU2010311640B2 (en) | 2015-01-29 |
| UY32969A (en) | 2011-05-31 |
| BR112012010114A2 (en) | 2017-08-08 |
| AR078763A1 (en) | 2011-11-30 |
| CA2777312A1 (en) | 2011-05-05 |
| JP2013507978A (en) | 2013-03-07 |
| NZ599114A (en) | 2014-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL214648A0 (en) | Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists | |
| HK1138022A1 (en) | Polypeptides, antibody variable domains & antagonists | |
| IL201399A0 (en) | Polypeptides, antibody variable domains and antagonists | |
| IL218860A0 (en) | Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists | |
| IL252561B (en) | Anti-siglec-15 antibodies, polynucleotides encoding the same, compositions comprising the same and uses thereof | |
| IL232009A (en) | Isolated, alpha4beta7 heterodimer specific antigen binding protein and various aspects related thereto | |
| HK1147269A1 (en) | Anti-vegf antibodies vegf | |
| ZA201008993B (en) | Anti-human interleukin-20 antibodies | |
| EP2304440A4 (en) | Novel monoclonal antibodies against hpv proteins | |
| ZA201105323B (en) | Agonists and antagonists of the sip5 receptor,and methods of uses thereof | |
| EP2331579A4 (en) | Monoclonal antibodies | |
| ZA201103588B (en) | Polypeptides,antibody variable domains & antagonists | |
| AP2012006276A0 (en) | New CCR2 receptor antagonists and uses thereof. | |
| IL236236A (en) | Fam26f polypeptide antibodies | |
| SG10201601279SA (en) | Monoclonal Antibody STRO-4 | |
| EP2354161A4 (en) | Anti-nr10 antibody, and use thereof | |
| GB0811298D0 (en) | Characterising polypeptides | |
| IL200168A0 (en) | Monoclonal anti-cxcl13 antibodies | |
| HK1168871A1 (en) | Monoclonal antibodies | |
| EP2322562A4 (en) | Monoclonal antibody, and immunoassay using same | |
| EP2399934A4 (en) | Novel monoclonal antibody, and use thereof | |
| ZA201001260B (en) | Immunogenic polypeptides and monoclonal antibodies | |
| SI2354161T1 (en) | Anti-nr10 antibody, and use thereof | |
| HK1158977A1 (en) | Anti-ferroportin monoclonal antibodies and uses thereof | |
| GB0718834D0 (en) | Antibody fusions |